Save up to $150 - Purchase by Aug 22
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Access TIDES & RNA Insights Anytime, Anywhere
Book Now and Start Streaming TodaymRNA R&Dkeyboard_arrow_right
Search keyboard_arrow_right
keyboard_arrow_left Hide
mRNA R&D
search
mRNA R&D
search
mRNA R&D 00:00 - 00:30
Targeting Obesity with RNAi-based Therapies
- James Hamilton, MD - Vice President of Clinical Research, Arrowhead Pharmaceuticals
mRNA R&D 00:30 - 01:00
Treating Argininosuccinic aciduria by Leveraging an mRNA Therapeutic To Correct Glutathione Metabolism
- Julien Barteau - Group Leader, UCL
mRNA R&D 01:00 - 01:30
Characterisation and analysis of mRNA vaccines/therapeutics using mass spectrometry
- Mark Dickman - Professor, University of Sheffield
mRNA R&D 01:30 - 02:00
Strategies for tissue targeting of mRNA therapeutics for immunomodulation in inflammatory diseases
- Jenny van Asbeck-van der Wijst - CEO, Mercuna
mRNA R&D 02:00 - 02:30
Circular RNA expression systems for enhanced gene and cell therapies
- Erik Digman Wiklund - CEO, Circio
mRNA R&D 02:30 - 03:00
A strategy to establish safe and effective mRNA-based therapeutics
- Akiko Yanagiya, PhD - Team Leader, Arcalis
mRNA R&D 03:00 - 03:30
A thermostable polymeric nanoparticle delivery platform: exploring PNP-mRNA vaccines against infectious diseases
- Michiel Lodder - CEO, 20Med Therapeutics
mRNA R&D 03:30 - 04:00
Development of an mRNA Based Off-The-Shelf Cancer Vaccine for Treatment Of Glioblastoma
- Myriam Mendila - Chief Scientific Officer, CureVac
mRNA R&D 04:00 - 04:30
Optimized self-replicating RNA enable low dose and single dose vaccine applications in the clinic
- Nathaniel Wang, PhD - CEO, Replacate Biosciecne
mRNA R&D 04:30 - 05:00
Biofoundry-in-a-Box™: By-Design mRNA Manufacturing in a Box
- Harris Makatsoris - Academics Professor of Sustainable Manufacturing Systems, King's College London
mRNA R&D 05:00 - 05:30
mRNA Manufacturing: Mastering Impurity Detection and Removal for Enhanced Performance
- Jonathan Abysalh - Sr. Director, US Section Head Process Development, Sanofi
mRNA R&D 05:30 - 06:00
Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics
- Ying Tam, PhD - Chief Scientific Officer, Acuitas Therapeutics
mRNA R&D 06:00 - 06:30
Adapting LNP Platform Manufacturing Methods to Enable Clinical Applications of Next Generation mRNA-LNP Therapeutics
- Ed Yaworski - Chief Technology Officer, Genevant Sciences Corp
mRNA R&D 06:30 - 07:00
Translation of an Optimized Self-replicating RNA Platform with an Expanded Clinical Therapeutic Index
- Andrew Geall, PhD - Co-founder and Chief Development Officer, Replicate Bioscience
mRNA R&D 07:00 - 07:30
BioNTech’s Individualized Neoantigen Specific Immunotherapies Against Cancer: Concept and Clinical Update
- Andreas Kuhn, PhD - Senior Vice President RNA Biochemistry & CMC Development, BioNTech SE
mRNA R&D 07:30 - 08:00
mRNA Program for Rare Diseases
- Denesh Chitkara, MD - Clinical Programs in Rare Diseases, Moderna
mRNA R&D 08:00 - 08:30
RNA Modifications and Process Enhancements Significantly Improve the Potency of RNA Constructs in Preclinical Testing
- Kate Broderick, PhD - Chief Innovation Officer, Maravai LifeSciences
mRNA R&D 08:30 - 09:00
Complete Chemical Synthesis of mRNA for Cancer Vaccine
- Hiroshi Abe, PhD - Professor, Department of Chemistry, Graduate School, Nagoya University
mRNA R&D 09:00 - 09:30
Developing the Next Generation RSV Vaccine
- Dong Shen, MD, PhD - CEO, RNAimmune, Inc.
mRNA R&D 09:30 - 10:00
Lipid Nanoparticles for mRNA Vaccine Delivery
- Mate Vadovics, PhD - Postdoctoral Fellow, Norbert Pardi Lab, University of Pennsylvania
mRNA R&D 10:00 - 10:30
Targeting lncRNA TUG1 for Treatment of Patients with GBM by Using a Novel DDS System for ASO
- Shiro Akinaga, PhD - President and CEO, NANO MRNA, Co., Ltd.